SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · STE

STERIS Announces Financial Results for Fiscal 2027 First Quarter

STERIS plc · Filed · SEC Form 8-K, Item 2.02

STERIS plc company page Original on SEC.gov ↗

Revenue $1.5 billion +7% vs a year ago
EPS $2.04 not detected
Guidance maintainedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue climbed 7% year on year to $1.5 billion, and EPS was $2.04. The company kept its outlook unchanged, so the reported quarter did not change management's expectations for the periods ahead.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$1.5 billion +7% vs a year ago

…Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal…
EPS

$2.04

…Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59…
Guidance

Guidance maintained

…Our revenue and earnings expectations for the year are unchanged, as the strength of our portfolio continues to enable us to help our Customers navigate a complex operating environment.”. | The Company is reiterating its prior guidance for revenue and earnings for fiscal 2027.…

Read the original press release on SEC.gov ↗ Filing index ↗

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.